Streetbeat News

Products Services

PKOH

ParkOhio anticipates its 2024 revenues to grow in the mid-single digit range year-over-year, primarily due to strong demand in Supply Technologies and robust backlogs in Engineered Products.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:41 pm

ACRV

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) announced its participation in the AACR Annual Meeting in April 2024, where it will present data on its proprietary AP3 platform and development candidates, including ACR-2316, a novel WEE1/PKMYT1 inhibitor, and findings on overcoming resistance to ACR-368, a CHK1/2 inhibitor. The presentations will highlight the platform's ability to generate potent, selective agents and address drug resistance mechanisms.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:39 pm

MSFT

Microsoft Corp (NASDAQ:MSFT) announced the first wave of games for Xbox Game Pass in March 2024, featuring titles across Cloud, Console, and PC platforms. The lineup includes Warhammer 40,000: Boltgun, PAW Patrol World, SpongeBob SquarePants: Battle for Bikini Bottom – Rehydrated, Control Ultimate Edition, No More Heroes 3, Lightyear Frontier, and MLB The Show 24. Additionally, several games will be leaving Game Pass on March 15.

Portfolio Pulse from Franca Quarneti

March 05, 2024 | 9:39 pm

CRBU

Caribou Biosciences, Inc. (NASDAQ:CRBU) announced it will present preclinical data on CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy for r/r AML, at the AACR Annual Meeting 2024. CB-012, engineered with Caribou's CRISPR technology, shows promise in improving antitumor activity through unique genome edits.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:38 pm

ITOS

iTeos Therapeutics, Inc. (NASDAQ:ITOS) announced a poster presentation of preclinical data on EOS-984, targeting ENT1, at the AACR Annual Meeting 2024. The presentation will detail EOS-984's role in inhibiting ENT1 to relieve immune suppression.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:36 pm

TPST

Tempest announced it will present preclinical data for TPST-1120, targeting renal cell carcinoma, at the AACR Annual Meeting. This showcases the company's progress in developing treatments for cancer.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:36 pm

ZYME

Zymeworks Inc. announced its participation in the AACR Annual Meeting with five abstracts accepted for poster presentations, showcasing advancements in antibody-drug conjugate and multispecific antibody therapeutics. The presentations will cover the preclinical activity of ZW191, a FRα-targeting antibody-drug conjugate, and next-generation trispecific T cell engagers with CD28 costimulation, demonstrating progress in developing treatments for difficult-to-treat diseases.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:35 pm

RAPT

RAPT Therapeutics, Inc. (NASDAQ:RAPT) announced the acceptance of three late-breaking abstracts for presentation at the AACR Annual Meeting in April 2024, including phase 2 clinical data on tivumecirnon (FLX475) for head and neck squamous cell carcinoma. The presentations will cover the efficacy of FLX475 in combination with pembrolizumab, a combined mregDC and Treg signature's association with antitumor efficacy, and the role of HPK1 in CD8+ T cell effector gene expression.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:34 pm

ME

23andMe announced its participation in the American Association for Cancer Research Annual Meeting 2024 with three presentations from its clinical-stage immuno-oncology programs. This showcases the company's progress in cancer research and its commitment to advancing cancer treatments.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:34 pm

ALXO

ALX Oncology Holdings Inc. (NASDAQ:ALXO) announced that two clinical abstracts related to its drug evorpacept have been accepted for presentation at the AACR Annual Meeting in San Diego. The presentations will cover a Phase 1 trial in B-cell non-Hodgkin lymphoma and a study on myelodysplastic syndrome, showcasing ALX Oncology's advancements in immuno-oncology.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:33 pm